Multicentre clinical trial of antirejection pulse therapy with deoxyspergualin in kidney transplant patients.
The present randomized comparative clinical trial was carried out to confirm the efficacy of a newly developed immunosuppressive drug, 15-deoxyspergualin (DSG), and also to find its optimal dose for antirejection pulse therapy. The study included 66 patients with rejection which had occurred within 6 months after renal transplantation. They were treated with DSG at 3, 5 or 7 mg/kg/day for 5 days. The overall percentage of efficacy was 73% and the percentage of efficacy was the highest in the 3-mg/kg group (82%). The incidence of adverse reaction tended to be dose-dependent. From these results, the optimal dose of DSG was judged to be 3-5 mg/kg/day for antirejection pulse therapy, and at doses in this range the percent efficacy could be expected to be 80% or more.